INSP INVESTORS: Inspire Medical Systems, Inc. Stock Drops 32% after Inspire V Delays Announced – Contact BFA Law by January 5 Securities Class Action Deadline

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, but failed to prepare clinicians and payors, leading to significant delays and weak demand [5][6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].